Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.23+0.01 (+6.53%)
Close on Nov 17, 2026Market cap $16.64MP/E –Yield –
Acumen Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Acumen Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$87.95M. For fiscal 2025 it was -$115.54M. The highest annual figure on record is -$7.45M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$115.54M | – |
| FY2024 | Dec 31, 2024 | -$86.22M | – |
| FY2023 | Dec 31, 2023 | -$43.06M | – |
| FY2022 | Dec 31, 2022 | -$35.15M | – |
| FY2021 | Dec 31, 2021 | -$17.96M | – |
| FY2020 | Dec 31, 2020 | -$7.45M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$26.65M | – |
| Q2 FY2026 | Jun 30, 2026 | -$18.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.55M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.18M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.64M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.86M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.28M | – |
See a number that looks wrong?